BETWEENAnd Development Agreement • November 15th, 2005 • Sense Holdings Inc • Miscellaneous manufacturing industries
Multi-Laboratory Single Participant ChemCatBio CRADAAnd Development Agreement • August 26th, 2021
Background Intellectual Property, which was in existence prior to or is first produced outside of this CRADA, except that in the case of inventions in those identified items, the inventions must have been conceived outside of this CRADA and not first actually reduced to practice under this CRADA to qualify as Background Intellectual Property.
EX-10.12 34 d358280dex10121.htm COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA #2264) [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule...And Development Agreement • May 5th, 2020 • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
THIRD AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENTAnd Development Agreement • June 2nd, 2014 • Ulthera Inc • Electromedical & electrotherapeutic apparatus • Arizona
This THIRD AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENT (the “Third Restated Agreement”) is made effective as of August 26, 2013 (the “Effective Date”) by and among Guided Therapy Systems, LLC, an Arizona limited liability company (“GTS” or “Licensor”), Ardent Sound Inc., an Arizona corporation (“Ardent Sound” and, together with GTS, “Licensors”), and Ulthera, Inc., a Delaware corporation (“Ulthera” or “Licensee”). GTS or GTS and Ardent Sound, collectively, are hereinafter referred to as a “Party,” Ulthera is hereinafter referred to as a “Party,” and each of GTS, Ardent Sound and Ulthera are hereinafter collectively referred to as the “Parties.”
AMENDED AND RESTATED SUPPLY, LICENSE, AND DEVELOPMENT AGREEMENTAnd Development Agreement • May 25th, 2006 • VeriChip CORP • Communications equipment, nec • Minnesota
THIS AMENDED AND RESTATED SUPPLY, LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), is dated as of the 27th day of December, 2005 by and between DIGITAL ANGEL CORPORATION, a Delaware corporation (“Company”), and VERICHIP CORPORATION, a Delaware corporation (“VeriChip”).
As Operator of [Insert Lab Name] under its U.S. Department of Energy Contract AddressAnd Development Agreement • June 3rd, 2021
RECITALSAnd Development Agreement • May 9th, 2005 • Icu Medical Inc/De • Surgical & medical instruments & apparatus • New York
Multi-Laboratory Multi-Participant HydroGEN CRADAAnd Development Agreement • January 3rd, 2019
LANL MODULAR CRADA STEVENSON-WYDLER (15 USC 3710) COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (hereinafter "CRADA") NO. LA98CIO384 BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA under its U.S. Department of Energy Contract No. W@-7405-ENG-36...And Development Agreement • October 7th, 1999 • DCH Technology Inc • Industrial inorganic chemicals
PROPERTY USE AND DEVELOPMENT AGREEMENTAnd Development Agreement • April 14th, 2014
Grantors: 1) Teel, Vander Pol and Teel, a Washington limited partnership as to Parcels A, C, D, F, G, I, K, L, O, P,R and S 2) Teel Investment Company as to Parcel M 3) Teel & Madden, a Washington general partnership as to Parcels J and Q 4) Daryl Vander Pol, E. Gerald Teel and Charles B. Teel, all as their separate property, a partnership as to Parcel H 5) Teel, Vander Pol and Teel, a Washington limited partnership, as to an undivided 1/2 interest and E. Gerald Teel and Daryl Lee VanderPol, the co-personal representatives of the Estate of Edwin A. Teel as to an undivided 1/2 interest as to Parcel E Additional on page Grantee: 1) City of Seattle Additional on page Legal Description (abbreviated): Lots 7-11, Block 34; Lots 7-9, Block 33; Lots 1-7, Block 35; Lots 1-12, Block 36; Lots 3-4,Block 37; Lot 5 Block 38; Lots 1-9 and 12-13, Block 39 of Woodlawn Add. to Green Lake, according to the plat thereof recorded in Vol. 6, Page 20, in King County, Washington Addition
BERETTA HOLDING ACQUIRES STAKE IN CALZATURIFICIO ZAMBERLAN SRL, ANNOUNCES PRODUCTION AND DEVELOPMENT AGREEMENTAnd Development Agreement • September 26th, 2022
(SOLANA BEACH, CA – December 23, 2016) – Beretta Holding of Gardone Val Trompia (BS), Italy has acquired a 40% stake in Zamberlan USA’s parent company Calzaturificio Zamberlan Srl of Torrebelvicino (VI), Italy. The two companies have concurrently entered into a new footwear development and production agreement.
REGO II MANAGEMENT AND DEVELOPMENT AGREEMENTAnd Development Agreement • February 25th, 2008 • Alexanders Inc • Real estate investment trusts • New York
THIS REGO II MANAGEMENT AND DEVELOPMENT AGREEMENT dated as of the 20th day of December, 2007 (the “Management Agreement”) between ALEXANDER’S OF REGO PARK II, INC., a Delaware corporation, having an office c/o Vornado Realty Trust, 888 Seventh Avenue, New York, New York 10019 (collectively “Owner”) and VORNADO REALTY L.P., a Maryland limited partnership having an office at c/o Vornado Realty Trust, 888 Seventh Avenue, New York, New York 10019 (“Manager”).
AMENDMENT NO. X to COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN COOPERATOR NAME ANDAnd Development Agreement • May 12th, 2023
This "Amendment No. X" is entered into by and between Cooperator Name, a XXXX corporation with a principal place of business at Address (“the Cooperator”), and the EPA Center/Office (“the Center”) on behalf of the U.S. Environmental Protection Agency (“EPA” or the “Agency”) under the authority of Title 15, United States Code § 3710a, et seq. (commonly known as the Federal Technology Transfer Act of 1986).
THIRD AMENDMENT TO THE PRODUCT SUPPLY AND DEVELOPMENT AGREEMENTAnd Development Agreement • November 6th, 2017 • Nevro Corp • Surgical & medical instruments & apparatus
DEVELOPMENT AGREEMENT ("Amendment"), effective as of September 15, 2017 (the "Effective Date"), is by and between EaglePicher Medical Power LLC ("EPMP LLC"), a Delaware Corporation having an address of "C"and Porter Streets, Joplin, MO 64801 and Nevro Corp. ("Buyer"), a Delaware Corporation, having its principal place of business at 1800 Bridge Parkway, Redwood City, CA 94065 .
AND DEVELOPMENT AGREEMENT ADDENDUMAnd Development Agreement • February 25th, 2016
This document analyzes the Lagoon Valley phasing and development agreement in relation to the California Environmental Quality Act (CEQA). The Lower Lagoon Valley Policy Plan Implementation Project was approved in 2005. The supporting CEQA documentation consists of a 2004 Environmental Impact Report (EIR) for the Lower Lagoon Valley Specific Plan, and a 2005 Addendum to the EIR that considered changes to the project reflected in the Lower Lagoon Valley Policy Plan Implementation Project.
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCHAnd Development Agreement • February 27th, 2017 • Exelixis, Inc. • Services-commercial physical & biological research • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT Project Title: Radiation, Cell Cycle and Protein Kinase CAnd Development Agreement • May 15th, 2007 • Inhibiton Therapeutics, Inc. • Agricultural services • District of Columbia
This Cooperative Research and Development Agreement (CRADA), takes effect as of the last dated signature, is entered into by and between Inhibetex Therapeutics, Inc., hereinafter referred to as IT, Inc., and the VA Medical Center, Tampa, FL, a laboratory of Department of Veterans Affairs, hereinafter referred to as VA.
LICENSE, TRANSFER, AND DEVELOPMENT AGREEMENT BY AND AMONG SERENITY PHARMACEUTICALS LLC AND ALLERGAN SALES, LLC, ALLERGAN USA, INC., AND ALLERGAN, INC. MARCH 31, 2010, and Development Agreement • April 2nd, 2010 • Allergan Inc • Pharmaceutical preparations • New York
THIS LICENSE, TRANSFER, AND DEVELOPMENT AGREEMENT (the “Agreement”) is made and entered into as of March 31, 2010 (the “Effective Date”) by and among SERENITY PHARMACEUTICALS LLC, a Delaware limited liability company with a principal place of business at 105 Hawk Court, Milford, PA 18337 (“Serenity”), and ALLERGAN SALES, LLC, a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan Sales”), ALLERGAN USA, INC., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan USA”), and ALLERGAN, INC., a Delaware corporation with its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (“Allergan, Inc.” and, collectively with Allergan Sales and Allergan USA, “Allergan”). Serenity and Allergan are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Chief James R. Gray Osage Nation Pawhuska OK, 74056 Dear Chief Gray: Please consider this letter to be approval on the part of the Bureau of Indian Affairs (“BIA”), for the Exploration and Development Agreement dated October 18, 2006, between the...And Development Agreement • February 27th, 2009 • Constellation Energy Partners LLC • Crude petroleum & natural gas
This approval is made under authority granted in 25 CFR Part 226.2(f) which says in part “A contract may be entered into through competitive bidding as outlined in Section 22.6(b), negotiation, or a combination of both. . .” and “. . .The Superintendent may approve any such contract made by the Osage Tribal Council.”
CENTERS FOR DISEASE CONTROL AND PREVENTION MATERIALS COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTAnd Development Agreement • July 10th, 2013
This Materials Cooperative Research and Development Agreement (“M-CRADA”) has been adopted for use by the Centers for Disease Control and Prevention (“CDC”) for transfers of essential research material(s) from collaborators (hereinafter “Collaborator Research Material”) not otherwise reasonably available for CDC research. It consists of a copy of the CDC Model M-CRADA, a Signature Page, a Contacts Page, and a Summary Page. The research plan (“Research Plan”) is attached as Appendix A and all changes to this model agreement are collected in Appendix B. Appendices A and B are incorporated herein by reference. This M-CRADA involves no exchange of personnel or of any resources other than as described in Appendix A. This M-CRADA is made under authority of the Federal Technology Transfer Act, 15 U.S.C. § 3710a, and is governed by its terms.
THE SEATTLE CITY CLERKAnd Development Agreement • September 6th, 2013
Re: Binding Letter Agreement for Exploration and Development and MiningAnd Development Agreement • March 15th, 2006 • Miranda Gold Corp • Metal mining
The fraction set forth above shall be 70%/30% (for Equity Account purposes) if PDUS earns the Additional Interest, and 75%/25% (for Equity Account purposes) if PDUS earns the Supplemental Additional Interest, and the Participants will take such actions as are reasonably necessary to make the Capital Account balances reflect PDUS’s additional expenditures made to earn the Additional Interest and the Supplemental Additional Interest.
Learning and Development Agreement and Reclamation of Funds AgreementAnd Development Agreement • February 12th, 2015
As part of Blackpool Teaching Hospitals NHS Foundation Trusts commitment to support continued professional development and to enhance individual career prospects, it is important that you have access to learning and development to complement and maintain your skills and experience.
AMENDMENT NO. 1And Development Agreement • August 9th, 2007 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 1 (the “Amendment”) amends the MANUFACTURING, COMMERCIALIZATION AND DEVELOPMENT AGREEMENT (the “Agreement”) entered into as of July 31, 2006 between ISIS PHARMACEUTICALS, INC., a Delaware corporation, through its IBIS BIOSCIENCES division (“Ibis”), and BRUKER DALTONICS INC., a Delaware corporation (“Bruker”) and is effective on the date both parties have signed below.
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCHAnd Development Agreement • September 4th, 2012 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
Cooperative Research and Development Agreement (CACR - 0774) Clinical Development of Perifosine Sherry Ansher, Ph.D. Janet Dancey, M.D. CTEP DCTD Dr. rer. nat. Rainer Voegeli ASTA Medica, Inc. Prepared by Technology Development and Commercialization...And Development Agreement • March 30th, 2004 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations • District of Columbia
This Cooperative Research and Development Agreement, hereinafter referred to as the “CRADA,” consists of this Cover Page, and attached Agreement, and various Appendices referred in the Agreement. This Cover Page serves to identify the Parties to this CRADA:
FIRST AMENDMENT TO LICENSE, SERVICES, AND DEVELOPMENT AGREEMENT (FOR MARRIOTT PROJECTS)And Development Agreement • February 27th, 2018 • MARRIOTT VACATIONS WORLDWIDE Corp • Real estate agents & managers (for others)
This First Amendment to License, Services, and Development Agreement (this “Amendment”) is executed as of February 26, 2018 by Marriott International, Inc., a Delaware corporation (“MII”), and Marriott Worldwide Corporation, a Maryland corporation (“MWC”) (MII and MWC are referred to collectively herein as “Licensor”), and Marriott Vacations Worldwide Corporation, a Delaware corporation (“Licensee”).
NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTAnd Development Agreement • May 5th, 2020
This Cooperative Research and Development Agreement (CRADA or Agreement) between the National Institute of Standards and Technology (NIST) and [Collaborator’s Name] (Collaborator) will be effective when signed by all Parties (Effective Date), entered into by NIST under its authority under Title 15, United States Code section 3710a. The research and development activities which will be undertaken by the Parties in the course of this CRADA are detailed in the Research Plan which is attached as part of Appendix A. Any exceptions or changes to the terms of the CRADA are set forth in Appendix B. NIST and Collaborator may also be referred to individually as “Party” or collectively as “Parties.”
THIRD AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENTAnd Development Agreement • March 3rd, 2014 • Ulthera Inc • Electromedical & electrotherapeutic apparatus • Arizona
This THIRD AMENDED AND RESTATED LICENSE AND DEVELOPMENT AGREEMENT (the “Third Restated Agreement”) is made effective as of August 26, 2013 (the “Effective Date”) by and among Guided Therapy Systems, LLC, an Arizona limited liability company (“GTS” or “Licensor”), Ardent Sound Inc., an Arizona corporation (“Ardent Sound” and, together with GTS, “Licensors”), and Ulthera, Inc., a Delaware corporation (“Ulthera” or “Licensee”). GTS or GTS and Ardent Sound, collectively, are hereinafter referred to as a “Party,” Ulthera is hereinafter referred to as a “Party,” and each of GTS, Ardent Sound and Ulthera are hereinafter collectively referred to as the “Parties.”
FIRST AMENDMENT TO THE AMENDED AND RESTATED DISPOSITION AND DEVELOPMENT AGREEMENTAnd Development Agreement • March 4th, 2011
AND DEVELOPMENT AGREEMENT (the “First Amendment”) by and between the REDEVELOPMENT AGENCY OF THE CITY OF SAN DIEGO, a public body corporate and politic (the “Agency”), and THE MONARCH SCHOOL PROJECT, a California non- profit corporation (the “Developer”), is entered into as of the date signed by the Agency. The Agency and Developer are collectively referred to herein as the “Parties.”
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA)And Development Agreement • August 17th, 2007
This Cooperative Research and Development Agreement (CRADA) between the National Oceanic and Atmospheric Administration (NOAA), on behalf of the National Environmental Satellite, Data, and Information Service (NESDIS), and the Collaborator will be effective when signed by all Parties. The research and development project(s) which will be undertaken by each of the Parties in the course of this CRADA is detailed in the Statement of Work (SoW) which is attached as part of Appendix A. Any exceptions or changes to the CRADA are set forth in Appendix B.
This Agreement is dated the _ day of , 201 . BETWEEN: Canyon Beach Properties Ltd.And Development Agreement • October 8th, 2014 • Saskatchewan
This document serves as the standard Architectural Controls, Building Specifications and Development Agreement between the property Owner and the Developer.
INHIBIKASE THERAPEUTICS FIRST AMENDMENT TO COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTAnd Development Agreement • October 16th, 2018 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with an effective date as of the 5th day of October 2012 (the “Amendment Effective Date”) by and among, on the one hand, Inhibikase Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway, Suite 1927, Atlanta, Georgia (the “Company”) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and Sphaera Pharma Pvt. Ltd., with its registered office at E-375, First Floor, Greater Kailash-II, New Delhi-110048, INDIA (“Sphaera India”)(together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”). (Company and Sphaera Pharma shall be referred to individually as a “Party” and collectively as the “Parties.”) Except as otherwise provided in this Agreement, capitalized terms and phrases
SITE LOCATION AND DEVELOPMENT AGREEMENTAnd Development Agreement • December 23rd, 2021 • Adit EdTech Acquisition Corp. • Blank checks • Tennessee
THIS SITE LOCATION AND DEVELOPMENT AGREEMENT (this “Agreement”) is hereby made and entered into as of the 28 day of September, 2020 (the “Effective Date”), by and among RED DOG TECHNOLOGIES LLC (the “Company”) and JOHNSON CITY ENERGY AUTHORITY D/B/A BRIGHTRIDGE (“BrightRidge”). Company and BrightRidge may from time to time be referred to individually as a “Party” and collectively as the “Parties.”
under its U.S. Department of Energy Contract No. DE-AC05-00OR22725 (hereinafter “Contractor”)And Development Agreement • July 24th, 2015
